Benefit-risk assessment conceptual framework for exposure to biologics during pregnancy

被引：0
|
作者：
Bozzi, Laura [1 ]
Jacobson, Melanie H. [2 ]
Yost, Emily [3 ]
Cafone, Joseph [1 ]
Sheahan, Anna [4 ]
Levitan, Bennett S. [1 ]
Nelson, Robert M. [5 ]
机构：
[1] Janssen Pharmaceut, Beerse, Belgium
[2] Janssen Res & Dev, Raritan, NJ USA
[3] Janssen, Beerse, Belgium
[4] Janssen Res & Dev LLC, Raritan, NJ USA
[5] Johnson & Johnson, New Brunswick, NJ USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
1124
引用
收藏
页码：529 / 529
页数：1
相关论文
共 50 条
  • [41] Benefit-risk assessment for binary diagnostic tests
    Bai, Tianyu
    Huang, Lan
    Li, Meijuan
    Tiwari, Ram
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2019, 29 (05) : 760 - 775
  • [42] Benefit-risk assessment: industry and regulatory perspectives
    Reactions Weekly, 2001, 882 (1) : 3 - 4
  • [43] Drug intake and pregnancy, evaluating the benefit-risk balance
    Benevent, Justine
    Lacroix, Isabelle
    ACTUALITES PHARMACEUTIQUES, 2019, 58 (588): : 21 - 27
  • [44] Benefit-risk assessment of rofecoxib in the treatment of osteoarthritis
    Schmidt, H
    Woodcock, BG
    Geisslinger, G
    DRUG SAFETY, 2004, 27 (03) : 185 - 196
  • [45] Benefit-Risk Assessment of Sirolimus in Renal Transplantation
    Dirk R.J. Kuypers
    Drug Safety, 2005, 28 : 153 - 181
  • [46] Benefit-Risk Assessment of Rofecoxib in the Treatment of Osteoarthritis
    Helmut Schmidt
    Barry G. Woodcock
    Gerd Geisslinger
    Drug Safety, 2004, 27 : 185 - 196
  • [47] Benefit-risk assessment of sirolimus in renal transplantation
    Kuypers, DRJ
    DRUG SAFETY, 2005, 28 (02) : 153 - 181
  • [48] Bayesian Approach to Personalized Benefit-Risk Assessment
    Cui, Shiqi
    Zhao, Yueqin
    Tiwari, Ram C.
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2016, 8 (03): : 316 - 324
  • [49] A benefit-risk assessment of basiliximab in renal transplantation
    Boggi, U
    Danesi, R
    Vistoli, F
    Del Chiaro, M
    Signori, S
    Marchetti, P
    Del Tacca, M
    Mosca, F
    DRUG SAFETY, 2004, 27 (02) : 91 - 106
  • [50] Benefit-risk assessment of antileukotrienes in the management of asthma
    García-Marcos, L
    Schuster, A
    Pérez-Yarza, EG
    DRUG SAFETY, 2003, 26 (07) : 483 - 518
12345